Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

CAPS Rating: 3 out of 5

A biopharmaceutical company developing novel therapeutics based on RNA interference, which is a naturally occurring biological pathway within cells for selectively silencing and regulating specific genes.


Player Avatar jlanganki (22.00) Submitted: 12/7/2010 11:30:07 PM : Outperform Start Price: $9.63 ALNY Score: +895.47

Priced at near cash on hand, with bright prospects in the coming years.

Featured Broker Partners